Research desk · RPRX · Nasdaq

SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.

Royalty Pharma plc · Pharmaceutical Preparations

Royalty Pharma plc financial statements, chart, and peer compare from SEC filings.

Royalty Pharma plc (RPRX) discovers, develops, or markets pharmaceutical products.

Market cap
$34.1B
P/E
38.04
Op. margin
56.83%
Profit margin
48.48%
FCF margin
117.37%
ROE
12.14%

Related Health Care stocks: UTHR stock financials · BMRN stock financials · ALKS stock financials · JAZZ stock financials · EXEL stock financials

See Health Care moving on the anomaly desk

misprise.com
Constructive (60–72) TTM Updated October 18, 2026 9:33 pm ← Screener
Primary research · 02

RPRX financial statements

Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.

Primary research · 03

RPRX stock peer compare

Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.

Focus chart

Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.

Supporting · 04

RPRX stock peer headlines

Yahoo Finance RSS for RPRX and the names in Compare.

Ticker Date Headline
Loading headlines…
Supporting · 05

RPRX stock price chart

Overlays follow the Compare table.

Chart loads when you scroll here
Supporting · 06

RPRX stock — research snapshot

Screen strengths and watchouts for RPRX stock from the latest Misprise snapshot.

Strengths

  • Operating margin 56.8% — solid operating leverage.
  • Profit margin 48.5% — durable bottom-line quality.
  • FCF margin 117.4% — cash conversion looks healthy.
  • Current ratio 2.80 — liquidity cushion.

Watchouts

  • PEG 6.18 — valuation looks rich vs growth.
  • Rev CAGR 5Y 2.3%
  • Rev CAGR 3Y 2.1%
  • EPS CAGR 5Y 6.2%
  • EPS CAGR 3Y 161.1%
  • FCF CAGR 5Y 4.1%
  • FCF CAGR 3Y 5.1%
Supporting · 07

RPRX stock FAQs

Short answers for RPRX stock — statements, sector, and how this page is meant to be used.

What is RPRX stock?

Royalty Pharma plc (RPRX) discovers, develops, or markets pharmaceutical products. RPRX stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.

Where can I find Royalty Pharma plc financial statements?

Royalty Pharma plc financial statements — income statement, balance sheet, and cash flow — are on this RPRX stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

What happened to RPRX stock?

This page is a research snapshot of Royalty Pharma plc (RPRX) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

Does this page show the RPRX stock price?

The live chart on this RPRX stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

What sector is RPRX stock in?

Royalty Pharma plc is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.

How do I read RPRX financial statements?

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Where does the RPRX statement data come from?

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

Where can I find the RPRX income statement, balance sheet, and cash flow?

On this RPRX stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

What is the Misprise Score for RPRX stock?

RPRX stock currently scores 62/100 (Constructive (60–72)). Royalty Pharma plc is constructive on the screen — worth a deeper look at compounding and filings before treating it as high conviction. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

How is the RPRX comparison winner decided?

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

What is the Anomaly Score on this RPRX page?

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

What does the green grant dot mean on RPRX stock?

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

Is RPRX stock a buy?

No recommendation either way. This RPRX stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Royalty Pharma plc.